West Syndrome Market Report 2026

The west syndrome market size has grown strongly in recent years. It will grow from $1.11 billion in 2025 to $1.2 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to improved recognition of rare pediatric neurological disorders, availability of established anticonvulsant therapies, expansion of pediatric neurology centers, increasing hospital-based treatment access, rising awareness among healthcare professionals.

The west syndrome market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing investments in rare disease drug development, growing focus on precision neurology treatments, expansion of early screening programs, rising adoption of novel therapeutic combinations, increasing clinical trial activity for pediatric epilepsy. Major trends in the forecast period include increasing focus on early diagnosis of infantile spasms, growing use of advanced neuroimaging and eeg monitoring, rising adoption of combination drug therapies, expansion of clinical research on rare neurological disorders, enhanced emphasis on treatment outcome tracking.

The rising research and development (R&D) spending on neurological illnesses is expected to drive the growth of the West syndrome market in the coming years. R&D spending on neurological illnesses refers to investments aimed at advancing the understanding, diagnosis, and treatment of neurological disorders. The increase in R&D spending is driven by the growing prevalence of neurological disorders, advancements in medical technology, heightened awareness and demand for innovative treatments, and substantial funding from both government and private sectors. Increased R&D investment supports the development of improved diagnostics, therapies, and treatment options, boosting growth in the West syndrome market. For instance, in May 2023, the National Institute of Neurological Disorders and Stroke (NINDS), a US-based government agency under the National Institutes of Health, received USD 2.809 billion in funding for 2023, with a slight increase to USD 2.825 billion requested for 2024 to support a wide range of neurological research initiatives. Therefore, rising R&D spending on neurological illnesses is fueling growth in the West syndrome market.

Key companies in the West syndrome market are focusing on developing innovative solutions, such as ready-to-use oral solutions of vigabatrin, to improve ease of administration, ensure accurate dosing, and enhance treatment compliance in infants and young children. These formulations are designed to deliver antiepileptic drugs, such as vigabatrin or adrenocorticotropic hormone (ACTH), in a patient-friendly manner. For example, in June 2024, Pryos Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for a ready-to-use oral solution of vigabatrin to treat infantile spasms. Vigabatrin works by irreversibly inhibiting GABA transaminase (GABA-T), the enzyme responsible for breaking down gamma-aminobutyric acid (GABA) in the brain. The resulting increase in GABA functions as a brake on excitatory processes that can trigger seizure activity.

In December 2024, H. Lundbeck A/S, a Denmark-based pharmaceutical company, acquired Longboard Pharmaceuticals Inc. for $2.6 billion. Through this acquisition, Lundbeck gained access to bexicaserin, a 5-HT2C agonist in development for treating seizures associated with developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies. Longboard Pharmaceuticals Inc., a US-based clinical-stage biopharmaceutical company, specializes in developing innovative therapies for seizures associated with DEEs, including West syndrome.

Major companies operating in the west syndrome market are Takeda Pharmaceuticals, Jazz Pharmaceuticals, UCB S.A., H. Lundbeck A/S, Mallinckrodt Pharmaceuticals plc, Marinus Pharmaceuticals Inc., Ovid Therapeutics Inc., GW Pharmaceuticals Limited, SK Biopharmaceuticals Co Ltd, Catalyst Pharmaceuticals Inc., Eisai Co Ltd, Neurelis Inc, Ultragenyx Pharmaceutical Inc, Sanofi S.A., Novartis AG, Pfizer Inc, GlaxoSmithKline plc, Recordati Rare Diseases, Bial Portela & Ca SA, Supernus Pharmaceuticals Inc, Praxis Precision Medicines, Encodia Therapeutics, Insys Therapeutics, Orphelia Pharma SA, Valerion Therapeutics, Retrophin Inc, Medice Arzneimittel Pütter GmbH & Co KG.

North America was the largest region in the west syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the west syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the west syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the west syndrome market by increasing costs of imported active pharmaceutical ingredients, diagnostic equipment, EEG systems, and specialized medical devices used in diagnosis and treatment. Hospitals and clinics in North America and Europe are most affected due to reliance on imported drugs and neurological monitoring equipment, while Asia-Pacific faces pricing pressure on pharmaceutical manufacturing inputs. These tariffs are increasing treatment costs and impacting therapy accessibility. At the same time, they are encouraging regional drug manufacturing, domestic formulation development, and localized supply chains for essential neurological medicines.

The west syndrome market research report is one of a series of new reports that provides west syndrome market statistics, including west syndrome industry global market size, regional shares, competitors with a west syndrome market share, detailed west syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the west syndrome industry. This west syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

West syndrome, also known as infantile spasms, is a rare neurological disorder that typically affects infants within their first year of life. It is characterized by sudden muscle contractions occurring in clusters, abnormal brain wave patterns called hypsarrhythmia, and developmental regression or stagnation. If left untreated, West syndrome can result in long-term cognitive and motor impairments.

The primary treatments of West syndrome are anticonvulsants, benzodiazepines, corticosteroids, and vitamin B. Anticonvulsants are a class of drugs used to prevent or reduce the severity and frequency of seizures in individuals with epilepsy or other seizure disorders, including infantile spasms. These medications can be administered via parenteral, oral, or other routes and are distributed through hospitals, online pharmacies, and retail pharmacies. The end users include hospitals, homecare providers, and clinics.

The west syndrome market consists of revenues earned by entities by providing services such as neuroimaging technologies, genetic testing services, rehabilitative services, specialized dietary programs, supportive care and patient counseling for managing infantile spasms and associated developmental delays. The market value includes the value of related goods sold by the service provider or included within the service offering. The west syndrome market includes sales of hormone therapies, ketogenic diet and developmental therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.